← Back to Clinical Trials
Recruiting NCT06830369

NCT06830369 Effect of a Virtual Reality Program on Patient Comfort in the Surgical Intensive Care Unit

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06830369
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire, Amiens
Condition Immersive Virtual Reality
Study Type INTERVENTIONAL
Enrollment 194 participants
Start Date 2025-09-12
Primary Completion 2027-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
HypnoVRusual health care

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 194 participants in total. It began in 2025-09-12 with a primary completion date of 2027-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Admission to a surgical intensive care unit (ICU) following major surgery is associated with a number of discomforts, not only related to the disease itself, but also to the care provided or the ICU environment itself (lights, sounds, pain, sleep deprivation, thirst...). This discomfort is real, and can be associated with psychological consequences. The investigators hypothesized that the use of immersive virtual reality (IVR) with HypnoVR® is feasible and can help reduce discomfort in intensive care.The ZION trial is a prospective, monocentric trial, randomizing 194 patients admitted in a surgical intensive care unit after a major surgery. The inclusion criterion are patients admitted in a surgical intensive care for at least 48 hours following major surgery (cardiac, thoracic or major abdominal surgery). Patients will be allocated to the intervention group (n=97) or the control group (n=97). In the intervention group, patients will receive IVR using HypnoVR®, twice a day, during the ICU stay (2 to 5 days). In the control group, postoperative care will be conducted according to standard cares without IVR. The primary endpoint will be the 18-items IPREA questionnaire on the day of ICU discharge. The secondary endpoints will include intensity of discomfort symptoms (anxiety, pain, dyspnea, thirst and sleep deprivation), incidence of delirium, cumulative morphine consumption at ICU discharge, length of ICU stay, and anxiety or depression at 1 month after discharge from intensive care and patient experience of device use.

Eligibility Criteria

Inclusion Criteria: * Patients over 18 years old * scheduled for a major surgery (cardiothoracic surgery or a major abdominal surgery) * Written informed consent from patient. * Admitted in a surgical ICU for a postoperative care for at least 48 hours. * Absence of delirium at inclusion (RASS and CAM-ICU scale) Exclusion Criteria: * Missing informed consent * Patient strictly under 18 years old * Inclusion in other study within the last 30 days * Pregnancy * Emergency hospitalization * Progressive sepsis * Patient transferred from another intensive care unit * Short-term life-threatening condition * Active psychiatric illness requiring antidepressant, antipsychotic or anxiolytic treatment * Mechanical ventilation \> 48 hours * Patient known to have cognitive disorders. * Unbalanced epilepsy * Visual problems (absence of binocular vision, blindness) and/or auditory problems (deafness) preventing the use of virtual reality * Pregnant or breast-feeding women * Patients under guardianship or deprived of their liberty * Patients not registered with the national social security system

Contact & Investigator

Central Contact

Colin DEVOS

✉ Devos.colin@chu-amiens.fr

📞 33+322087899

Frequently Asked Questions

Who can join the NCT06830369 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Immersive Virtual Reality. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06830369 currently recruiting?

Yes, NCT06830369 is actively recruiting participants. Contact the research team at Devos.colin@chu-amiens.fr for enrollment information.

Where is the NCT06830369 trial being conducted?

This trial is being conducted at Amiens, France.

Who is sponsoring the NCT06830369 clinical trial?

NCT06830369 is sponsored by Centre Hospitalier Universitaire, Amiens. The trial plans to enroll 194 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology